| pubmed-article:19276257 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19276257 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19276257 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:19276257 | lifeskim:mentions | umls-concept:C1831593 | lld:lifeskim |
| pubmed-article:19276257 | lifeskim:mentions | umls-concept:C1514463 | lld:lifeskim |
| pubmed-article:19276257 | lifeskim:mentions | umls-concept:C0441772 | lld:lifeskim |
| pubmed-article:19276257 | lifeskim:mentions | umls-concept:C1706446 | lld:lifeskim |
| pubmed-article:19276257 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:19276257 | lifeskim:mentions | umls-concept:C0205460 | lld:lifeskim |
| pubmed-article:19276257 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:19276257 | pubmed:dateCreated | 2009-3-17 | lld:pubmed |
| pubmed-article:19276257 | pubmed:abstractText | Human interleukin-21 (IL-21) is a class I cytokine that mediates activation of CD8(+) T cells, natural killer (NK) cells, and other cell types. We report final clinical and biological results of a phase II study of recombinant human IL-21 (rIL-21) in patients with metastatic melanoma. | lld:pubmed |
| pubmed-article:19276257 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19276257 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19276257 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19276257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19276257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19276257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19276257 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19276257 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19276257 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:19276257 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:19276257 | pubmed:author | pubmed-author:CebonJonathan... | lld:pubmed |
| pubmed-article:19276257 | pubmed:author | pubmed-author:MouritzenUlri... | lld:pubmed |
| pubmed-article:19276257 | pubmed:author | pubmed-author:SkrumsagerBir... | lld:pubmed |
| pubmed-article:19276257 | pubmed:author | pubmed-author:FrederiksenKl... | lld:pubmed |
| pubmed-article:19276257 | pubmed:author | pubmed-author:KristjansenPa... | lld:pubmed |
| pubmed-article:19276257 | pubmed:author | pubmed-author:MillwardMicha... | lld:pubmed |
| pubmed-article:19276257 | pubmed:author | pubmed-author:SkakKrestenK | lld:pubmed |
| pubmed-article:19276257 | pubmed:author | pubmed-author:KeffordRichar... | lld:pubmed |
| pubmed-article:19276257 | pubmed:author | pubmed-author:DavisIan DID | lld:pubmed |
| pubmed-article:19276257 | pubmed:author | pubmed-author:HansenLasse... | lld:pubmed |
| pubmed-article:19276257 | pubmed:author | pubmed-author:McArthurGrant... | lld:pubmed |
| pubmed-article:19276257 | pubmed:author | pubmed-author:LundsgaardDor... | lld:pubmed |
| pubmed-article:19276257 | pubmed:author | pubmed-author:BradyBenB | lld:pubmed |
| pubmed-article:19276257 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19276257 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:19276257 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:19276257 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19276257 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19276257 | pubmed:pagination | 2123-9 | lld:pubmed |
| pubmed-article:19276257 | pubmed:meshHeading | pubmed-meshheading:19276257... | lld:pubmed |
| pubmed-article:19276257 | pubmed:meshHeading | pubmed-meshheading:19276257... | lld:pubmed |
| pubmed-article:19276257 | pubmed:meshHeading | pubmed-meshheading:19276257... | lld:pubmed |
| pubmed-article:19276257 | pubmed:meshHeading | pubmed-meshheading:19276257... | lld:pubmed |
| pubmed-article:19276257 | pubmed:meshHeading | pubmed-meshheading:19276257... | lld:pubmed |
| pubmed-article:19276257 | pubmed:meshHeading | pubmed-meshheading:19276257... | lld:pubmed |
| pubmed-article:19276257 | pubmed:meshHeading | pubmed-meshheading:19276257... | lld:pubmed |
| pubmed-article:19276257 | pubmed:meshHeading | pubmed-meshheading:19276257... | lld:pubmed |
| pubmed-article:19276257 | pubmed:meshHeading | pubmed-meshheading:19276257... | lld:pubmed |
| pubmed-article:19276257 | pubmed:meshHeading | pubmed-meshheading:19276257... | lld:pubmed |
| pubmed-article:19276257 | pubmed:meshHeading | pubmed-meshheading:19276257... | lld:pubmed |
| pubmed-article:19276257 | pubmed:meshHeading | pubmed-meshheading:19276257... | lld:pubmed |
| pubmed-article:19276257 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19276257 | pubmed:articleTitle | Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. | lld:pubmed |
| pubmed-article:19276257 | pubmed:affiliation | Ludwig Oncology Unit, Austin Health, Melbourne, Victoria, Australia. | lld:pubmed |
| pubmed-article:19276257 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19276257 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19276257 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19276257 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19276257 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19276257 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19276257 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19276257 | lld:pubmed |
